Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cancer Res. 2013 Feb 25;73(9):2897–2904. doi: 10.1158/0008-5472.CAN-12-3980

Figure 5.

Figure 5

Serum ALT, liver IL-6 and TNF-α expression, and proliferation in DEN-treated wild-type and GSNOR−/− mice. A, Serum ALT levels assessed two days after DEN challenge (25 μg/g). The data (mean ± SD) are from five wild-type and five GSNOR−/− mice. B, Relative IL-6 and TNF-α mRNA levels after DEN treatment in four paired wild-type (filled) and GSNOR−/−(open) mice. IL-6 and TNF-α mRNA levels, analyzed by quantitative RT-PCR and normalized to GAPDH mRNA levels, are not statistically different between wild-type and GSNOR−/− mice (PIL-6 = 0.54, PTNF-α = 0.1). C, IL-6 and TNF-α protein levels after DEN treatment in four paired wild-type (filled) and GSNOR−/− (open) mice. The cytokine levels are not statistically different between wild-type and GSNOR−/− mice (PIL-6 = 0.08, PTNF-α = 0.64). D, Quantification of immunohistochemical staining for Ki-67 in livers of DEN-treated mice. Liver samples were collected 48 hours after DEN injection (25 μg/g) into 15-day-old wild-type (n = 5) and GSNOR−/− (n = 6) mice. In all panels, the data are mean ± SD.

HHS Vulnerability Disclosure